autologous anti-CD22 CAR-T cells CLIC-2201

A preparation of autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD22, with potential antineoplastic activity. Upon administration, autologous anti-CD22 CAR-T cells CLIC-2201 recognize and kill CD22-expressing tumor cells. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B cells.